CU23701A1 - Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i - Google Patents

Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i

Info

Publication number
CU23701A1
CU23701A1 CU20080254A CU20080254A CU23701A1 CU 23701 A1 CU23701 A1 CU 23701A1 CU 20080254 A CU20080254 A CU 20080254A CU 20080254 A CU20080254 A CU 20080254A CU 23701 A1 CU23701 A1 CU 23701A1
Authority
CU
Cuba
Prior art keywords
type
treatment
peptide
diabetes
inflammatory diseases
Prior art date
Application number
CU20080254A
Other languages
English (en)
Inventor
Valdes Ivon Menendez
Cama Viviana Falcon
Betancourt Ariana Barbera
Perez Norailys Lorenzo
Horta Maria Del Carmen Dominguez
Palomares Gabriel Ramon Padron
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20080254A priority Critical patent/CU23701A1/es
Priority to CA2748493A priority patent/CA2748493C/en
Priority to PCT/CU2009/000009 priority patent/WO2010075824A1/es
Priority to MX2011007033A priority patent/MX2011007033A/es
Priority to DK09804226.0T priority patent/DK2374468T3/da
Priority to US13/142,471 priority patent/US8410057B2/en
Priority to AU2009335405A priority patent/AU2009335405B2/en
Priority to KR1020117017870A priority patent/KR101620341B1/ko
Priority to JP2011543973A priority patent/JP5646506B2/ja
Priority to RU2011131872/15A priority patent/RU2524630C2/ru
Priority to BRPI0923832-8A priority patent/BRPI0923832B1/pt
Priority to ES09804226.0T priority patent/ES2438096T3/es
Priority to CN200980156252.0A priority patent/CN102307587B/zh
Priority to EP09804226.0A priority patent/EP2374468B1/en
Priority to ZA2011/05320A priority patent/ZA201105320B/en
Publication of CU23701A1 publication Critical patent/CU23701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con el campo de la medicina, particularmente con el uso de péptido tipo APL, derivado de la proteína de estrés térmico de 60 kDa humana, o sus análogos para la fabricación de una composición farmacéutica para el tratamiento de la enfermedad de Crohn, la colitis ulcerosa y la diabetes mellitus tipo I. Dicho péptido se biodistribuye al tracto gastrointestinal y promueve la inducción de apoptosis de células T activadas de la lámina propia intestinal y de la sangre periférica de pacientes con la enfermedad de Crohn. Además, este péptido induce apoptosis en células mononucleares de pacientes con diabetes mellitus tipo I.
CU20080254A 2008-12-29 2008-12-29 Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i CU23701A1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU20080254A CU23701A1 (es) 2008-12-29 2008-12-29 Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
CA2748493A CA2748493C (en) 2008-12-29 2009-12-29 Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes
PCT/CU2009/000009 WO2010075824A1 (es) 2008-12-29 2009-12-29 Uso de peptido tipo apl para el tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
MX2011007033A MX2011007033A (es) 2008-12-29 2009-12-29 Uso de peptido tipo apl para el tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i.
DK09804226.0T DK2374468T3 (da) 2008-12-29 2009-12-29 Anvendelse af peptid af APL-typen til behandling af inflammatoriske tarmsygdomme og type 1-diabetes
US13/142,471 US8410057B2 (en) 2008-12-29 2009-12-29 Method of inducing T cell apoptosis by administering Altered Peptide Ligand
AU2009335405A AU2009335405B2 (en) 2008-12-29 2009-12-29 Use of an APL peptide for the treatment of inflammatory bowel disease and type 1 diabetes
KR1020117017870A KR101620341B1 (ko) 2008-12-29 2009-12-29 염증성장질환 및 1형 당뇨병치료를 위한 ａｐｌ 펩티드의 사용
JP2011543973A JP5646506B2 (ja) 2008-12-29 2009-12-29 腸の炎症性疾患及び１型糖尿病を治療するためのａｐｌ型ペプチドの使用
RU2011131872/15A RU2524630C2 (ru) 2008-12-29 2009-12-29 Применение apl пептида для лечения воспалительной болезни кишечника и диабета типа 1
BRPI0923832-8A BRPI0923832B1 (pt) 2008-12-29 2009-12-29 Uso de um peptídeo tipo apl para o tratamento de doenças inflamatórias intestinais e diabetes tipo 1.
ES09804226.0T ES2438096T3 (es) 2008-12-29 2009-12-29 Utilización de péptidos tipo LPA para el tratamiento de enfermedades inflamatorias intestinales y diabetes tipo 1
CN200980156252.0A CN102307587B (zh) 2008-12-29 2009-12-29 Apl肽用于治疗炎症性肠病和1型糖尿病的用途
EP09804226.0A EP2374468B1 (en) 2008-12-29 2009-12-29 Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes
ZA2011/05320A ZA201105320B (en) 2008-12-29 2011-07-19 Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20080254A CU23701A1 (es) 2008-12-29 2008-12-29 Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i

Publications (1)

Publication Number Publication Date
CU23701A1 true CU23701A1 (es) 2011-09-21

Family

ID=41820665

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20080254A CU23701A1 (es) 2008-12-29 2008-12-29 Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i

Country Status (15)

Country Link
US (1) US8410057B2 (es)
EP (1) EP2374468B1 (es)
JP (1) JP5646506B2 (es)
KR (1) KR101620341B1 (es)
CN (1) CN102307587B (es)
AU (1) AU2009335405B2 (es)
BR (1) BRPI0923832B1 (es)
CA (1) CA2748493C (es)
CU (1) CU23701A1 (es)
DK (1) DK2374468T3 (es)
ES (1) ES2438096T3 (es)
MX (1) MX2011007033A (es)
RU (1) RU2524630C2 (es)
WO (1) WO2010075824A1 (es)
ZA (1) ZA201105320B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN115671253B (zh) * 2021-07-30 2024-02-27 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途
WO2024017423A1 (es) * 2022-07-22 2024-01-25 Centro De Ingenieria Genética Y Biotecnología Péptido para el tratamiento de enfermedades relacionadas con afectaciones en la apolipoproteina ai o la transtirretina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
US6180103B1 (en) * 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
BR9510102A (pt) * 1994-12-21 1997-11-25 Yeda Res & Dev Peptídeo uso do mesmo processo para diagnosticar a presenca ou o começo de diabetes mellitus dependente de insulina em um paciente kit para diagnosticar a presença de diabetes mellitus dependente de insulina preparação e processo para a prevenção ou tratamento do disbetes mellitus dependente de insulina e composição farmacêutica
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US6110746A (en) * 1995-06-30 2000-08-29 Yeda Research And Development Co. Ltd. Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
NZ519348A (en) * 1999-12-15 2006-04-28 Develogen Israel Ltd Fragments and antagonists of heat shock protein 60
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Also Published As

Publication number Publication date
AU2009335405A1 (en) 2011-08-25
US20120035106A1 (en) 2012-02-09
JP5646506B2 (ja) 2014-12-24
ES2438096T3 (es) 2014-01-15
EP2374468B1 (en) 2013-09-11
CN102307587A (zh) 2012-01-04
AU2009335405B2 (en) 2013-07-18
CN102307587B (zh) 2014-04-30
CA2748493C (en) 2017-08-22
JP2012514013A (ja) 2012-06-21
MX2011007033A (es) 2011-07-20
KR20110119677A (ko) 2011-11-02
CA2748493A1 (en) 2010-07-08
US8410057B2 (en) 2013-04-02
KR101620341B1 (ko) 2016-05-12
RU2524630C2 (ru) 2014-07-27
RU2011131872A (ru) 2013-02-10
DK2374468T3 (da) 2013-12-09
WO2010075824A1 (es) 2010-07-08
EP2374468A1 (en) 2011-10-12
ZA201105320B (en) 2012-04-25
BRPI0923832A2 (pt) 2015-07-21
BRPI0923832B1 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
Zhang et al. Microbiota transplantation: concept, methodology and strategy for its modernization
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
CU23701A1 (es) Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
CY1116552T1 (el) Ανοσοθεραπευτικα σχηματα εξαρτωμενα απο την κατασταση αροε
TR201818927T4 (tr) Kataterlerde İyileştirme
IN2014CN02448A (es)
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
DOP2012000066A (es) Moleculas anticuerpo anti-gcc y composiciones y metodos relacionados
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
WO2008087186A3 (en) Peptides for use in the treatment of obesity
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
WO2008087188A3 (en) Peptides for use in the treatment of obesity
CO6640324A2 (es) Uso de metformina en combinación con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa
DE602007002553D1 (de) Ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
CL2021002397A1 (es) Derivados de insulina sensibles a la glucosa
MY179250A (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
Reichardt et al. Chronic refractory osteomyelitis as a part of synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome: a diagnostic challenge
Kurt Ammer Thermology
TH112187A (th) การรักษาของเบาหวานในผู้ป่วยที่มีการควบคุมน้ำตาลในเลือดที่ไม่เพียงพอแม้จะรักษาด้วยยาต้านเบาหวานชนิดให้ทางปากหรือไม่ได้ให้ทางปาก
AR121038A1 (es) Derivados de insulina sensibles a glucosa
Ananev et al. Application of medical products on the basis of gelatin